> ## Content Index > Fetch the complete content index at: https://biopharmabrief.com/llms.txt > Use this file to discover other available public pages before exploring further. # ESMO 2026: Four Advances Shaping the Future of Cancer Care - URL: https://biopharmabrief.com/esmo-2026-four-advances-shaping-the-future-of-cancer-care/ - Published: 2026-10-28T13:00:00.000Z - Updated: 2026-10-28T16:39:41.000Z - Author: Logan Mavar *From personalized cancer vaccines to more sensitive methods of detecting recurrence, findings from ESMO 2026 highlight progress across cancer treatment and monitoring.* Cancer research is advancing on several fronts, with new therapies improving patient outcomes and increasingly sensitive technologies changing how disease can be detected and monitored. At the [2026 European Society for Medical Oncology (ESMO) Congress](https://www.esmo.org/?ref=biopharmabrief.com), held October 23–27 in Madrid, researchers presented clinical findings spanning personalized cancer vaccines, antibody-drug conjugates, T-cell engagers, and molecular diagnostics. Among the announcements were late-stage trials demonstrating improvements in disease control and survival, alongside new research aimed at detecting cancer recurrence earlier. Four developments stood out for their scientific significance and potential implications for cancer care. ## **Personalized Cancer Vaccines Deliver Phase 3 Results** Personalized cancer vaccines have long attracted scientific interest, but manufacturing a treatment tailored to each patient’s tumor presents technical and logistical challenges. New results from Moderna and Merck provide late-stage clinical evidence supporting this approach. At ESMO, the companies [presented Phase 3 INTerpath-001 results](https://www.modernatx.com/en-US/recapping-the-phase-three-interpath-results?ref=biopharmabrief.com) evaluating intismeran autogene, an investigational mRNA-based therapy, in combination with pembrolizumab (Keytruda) following surgical removal of high-risk melanoma. Intismeran is designed using genetic information from an individual patient’s tumor. Researchers identify mutations that produce potential neoantigens, then encode selected neoantigens into an mRNA therapy intended to stimulate T cells to recognize cancer cells carrying those targets. In the trial, the combination reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. The trial also met its key secondary endpoint of distant metastasis-free survival. The results provide evidence that individualized neoantigen therapy can improve outcomes when added to established immunotherapy. Overall survival data remain immature, and longer follow-up will be needed to assess whether the treatment improves overall survival. The manufacturing achievement is also noteworthy. Moderna reported successfully producing individualized treatments for more than 99% of patients randomized to receive intismeran, demonstrating that patient-specific therapies can be manufactured for a large international clinical trial. Commercial production will introduce additional demands involving manufacturing costs, turnaround times, and distribution. Still, the trial represents progress toward making individualized cancer vaccines a practical treatment option. ## **Antibody-Drug Conjugates Expand Their Role in Lung Cancer** ADCs have become one of oncology’s most active areas of drug development. These therapies use antibodies to deliver potent cytotoxic drugs to cells expressing specific molecular targets, aiming to improve efficacy while limiting toxicity. At ESMO, [results from the Phase 3 OptiTROP-Lung06 trial](https://en.prnasia.com/releases/apac/the-results-of-phase-iii-optitrop-lung06-study-of-sacituzumab-tirumotecan-sac-tmt-presented-as-an-esmo-oral-presentation-and-simultaneously-published-in-the-new-england-journal-of-medicine-553119.shtml?ref=biopharmabrief.com) demonstrated how ADCs could expand into first-line cancer treatment. The trial evaluated sacituzumab tirumotecan, a TROP2-targeting ADC developed by Sichuan Kelun-Biotech, in combination with pembrolizumab. The comparator was standard chemotherapy plus pembrolizumab in patients with previously untreated, advanced nonsquamous non-small cell lung cancer whose tumors lacked PD-L1 expression and actionable genomic alterations. The findings showed median progression-free survival of 15.0 months with the ADC combination compared with 5.7 months in the chemotherapy group. Grade 3 or higher treatment-emergent adverse events were less frequent overall with the ADC combination, although the treatments produced different toxicity profiles. Overall survival data remained immature at the interim analysis. The findings position sacituzumab tirumotecan as a potential alternative to conventional chemotherapy for this patient population, with substantially longer progression-free survival than the comparator regimen. They also illustrate a broader direction in ADC development. Improvements in antibody specificity, linker chemistry, and cytotoxic payloads are supporting the evaluation of these therapies in earlier treatment settings and alongside other drugs. For developers pursuing increasingly crowded ADC targets, the ability to demonstrate clinical advantages over established treatments will influence adoption and commercial potential. OptiTROP-Lung06 provides evidence of how a new ADC regimen could establish a place in first-line treatment, pending further evaluation of its survival benefit and safety profile. ## **T-Cell Engagers Show Survival Benefits Earlier in Treatment** Another notable presentation involved tarlatamab, a bispecific T-cell engager developed by Amgen for small cell lung cancer. Tarlatamab binds DLL3, a protein frequently expressed on small cell lung cancer cells, and CD3 on T cells. This brings immune cells into proximity with tumor cells, triggering T-cell-mediated killing. The drug [received accelerated FDA approval in 2024](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer?ref=biopharmabrief.com), followed by [traditional approval in November 2025](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer?ref=biopharmabrief.com), for patients with extensive-stage small cell lung cancer whose disease had progressed after platinum-based chemotherapy. The Phase 3 DeLLphi-305 trial investigated whether introducing tarlatamab earlier, as maintenance treatment alongside AstraZeneca’s durvalumab, could improve outcomes following initial chemotherapy and immunotherapy. According to [Amgen’s October 24 announcement](https://investors.amgen.com/news-releases/news-release-details/imdelltrar-combination-imfinzir-reduced-risk-death-unprecedented?ref=biopharmabrief.com), median overall survival reached 21.1 months with tarlatamab plus durvalumab compared with 12.7 months with durvalumab alone. These findings are especially relevant given the aggressive nature of extensive-stage small cell lung cancer, where maintaining disease control following initial treatment remains difficult. Safety remains an important consideration. Cytokine release syndrome occurred in nearly half of patients receiving the combination, although most cases were mild or moderate. Grade 3 or higher adverse events were also more frequent with the combination than with durvalumab alone. DeLLphi-305 provides evidence that introducing a T-cell engager earlier in treatment can produce a substantial survival benefit. The results also support further investigation of how bispecific therapies can complement existing immunotherapies. For developers pursuing T-cell engagers, expanding into earlier treatment settings could broaden the clinical applications of this drug class. Demonstrating that these benefits justify the additional toxicity and treatment burden will remain important as the approach advances. ## **Liquid Biopsy Advances Improve Detection of Residual Cancer** Advances in molecular diagnostics were another highlight at ESMO 2026, particularly in detecting cancer that may remain after treatment. On October 23, Abbott [announced results from its Beta-CORRECT study](https://abbott.mediaroom.com/2026-10-23-Abbott-presents-new-ESMO-data-showing-30-percent-absolute-improvement-in-sensitivity-with-the-whole-genome-sequencing-Oncodetect-R-test-in-colorectal-cancer?ref=biopharmabrief.com), evaluating an updated version of its Oncodetect liquid biopsy test in patients with colorectal cancer. The test detects circulating tumor DNA (ctDNA), small fragments of cancer-derived genetic material in the bloodstream. Using whole-genome sequencing, the updated technology tracks thousands of tumor-specific mutations to improve detection of molecular residual disease following treatment. The new test achieved 72.2% sensitivity for recurrence within two years of surgery, compared with 42.2% for the previous version, using a single postsurgical blood sample. Abbott [launched the updated Oncodetect test](https://abbott.mediaroom.com/2026-10-26-Abbott-launches-whole-genome-sequencing-Oncodetect-R-molecular-residual-disease-MRD-test-to-detect-traces-of-cancer-during-and-after-treatment?ref=biopharmabrief.com) on October 26, although it has not received FDA clearance or approval. Improved sensitivity could help clinicians identify patients at greater risk of recurrence and refine post-treatment monitoring. Further studies will be needed to determine whether using these results to guide care improves patient outcomes. ## **What ESMO 2026 Tells Us About Cancer Care** ESMO 2026 highlighted advances across the cancer care pathway, from reducing recurrence risk following surgery to improving survival in advanced disease and detecting molecular evidence of relapse. The findings also illustrate how differently these technologies must be evaluated. Randomized clinical trials can establish whether new treatments improve patient outcomes, while diagnostic studies must demonstrate that the information they provide can guide better clinical decisions. Each advance brings distinct challenges involving manufacturing, safety, clinical validation, or adoption. Addressing those challenges will help determine how these technologies fit into existing standards of care. As oncology research continues to expand the tools available to clinicians, the findings from Madrid offer a picture of progress across treatment and monitoring, along with the evidence still needed to translate these advances into routine patient care.